Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of ...
Verve Therapeutics, Inc. (VERV) has been making great progress in being able to advance its pipeline, that's because it has done well to advance its main clinical candidate in the pipeline known as ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Verve Therapeutics is expanding a gene editing trial ...
Recently shared results from Verve Therapeutics’ Phase 1b clinical trial add to the promise of gene-editing medicines one day becoming single-course therapies for heart disease. In what the company ...
Investors punished Verve Therapeutics (VERV) this week—but analysts were far more forgiving—after it voluntarily paused an early-stage clinical trial of one of its lead programs, VERVE-101, after one ...
The last time I wrote about Verve Therapeutics (VERV), it was in a Seeking Alpha article entitled "Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts." With ...
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli ...
BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene ...
SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback